Welcome to the July 2019 edition of The Journal of Clinical and Aesthetic Dermatology (JCAD). We begin this issue with an original research article titled, “An Oral Supplement and the Nutrition–Skin Connection,” in which Draelos evaluated the efficacy of a nutritional supplement for increasing skin hydration, reducing wrinkles, increasing energy, and improving quality of life and sleep. The study enrolled 50 female subjects, aged 35 to 65 years, with mild-to-moderate photoaging, who were instructed to take three tablets, morning and evening, of either the nutritional supplement or placebo. A blinded investigator rated a statistically significant improvement from baseline at Week 8 that continued into Week 12 among the participants in the active supplement group in terms of firmness, hydration, dullness, and overall skin appearance.
Next, results from original research conducted by Del Rosso are reported in an article titled, “Ceramide- and Keratolytic-containing Body Cleanser and Cream Application in Patients with Psoriasis: Outcomes from a Consumer Usage Study.” Here, Del Rosso evaluated the benefits of a body cleanser and cream containing ceramides, salicylic acid, and urea in patients with a history of psoriasis, including those with mild-to-moderate psoriatic flares. The study included male and female adult subjects with a history of mild-to-moderate psoriasis. Participants were instructed to use the cleanser two times per week and to apply the cream liberally to areas where psoriasis was present twice daily for two weeks. For the cream and cleanser together, 84.8 percent of the participants reported it provided relief of psoriasis, and 90.9 percent reported that their skin felt soft and smooth.
After this, a case series by Milam et al titled, “Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine” describes three female patients who developed either palmar flushing or spider angiomas after being treated with ado-trastuzumab emtansine for advanced breast cancer. All three patients with stigmata of liver disease that developed during the course of ado-trastuzumab emtansine demonstrated parenchymal liver abnormalities, revealed through abdominal computed tomography and magnetic resonance imaging in one patient and elastography in the other two. This led authors to recommend elastography studies for patients on ado-trastuzumab emtansine who present with spider angiomas and/or palmar flushing to ensure early structural liver damage is not occurring.
Next, in a case series by Mathis and Ibrahim titled, “Erbium-doped Yttrium Aluminium Garnet (Er:YAG) Laser Resurfacing Restores Normal Function and Cosmesis in Patients with Severe Rhinophyma,” the authors assessed the efficacy of Er:YAG laser resurfacing as a treatment modality for rhinophyma of all degrees. Eleven Caucasian male patients were classified as having mild, moderate, or severe rhinophyma, were treated with a dual mode Er:YAG fully ablative laser. In all 11 patients, Er:YAG treatment allowed for increased ablative precision, a decreased risk of complications, shorter downtime, and improved outcomes compared to currently available treatments.
Following this, the Dermatological Society of Singapore presents its consensus guidelines on acne management. The society developed these guidelines to provide comprehensive advice on individualized acne treatment and to provide a reference guide for all doctors who treat patients of Asian descent.
Next, in an original research article titled, “Comparison of Irritancy Potential of Sodium Lauryl Sulfate-free Aqueous Cream with Other Moisturizers: An Intraindividual Skin Occlusive Study,” Chan et al compared the irritancy potential of sodium lauryl sulfate (SLS)-free aqueous cream to SLS-containing aqueous cream and other moisturizers in 12 healthy volunteers. Ten formulations were applied with Finn chamber occlusion to different sites on each participant’s back for 72 hours. On Day 0, prior to moisturizer applications, and on Days 3 and 7, after application of the moisturizers and the removal of the patch test chambers, skin hydration and transepidermal water loss (TEWL) were measured. The SLS-free aqueous cream resulted in no significant changes in TEWL or skin hydration measurements throughout the study period, demonstrating a lower irritancy potential than SLS-containing cream, which caused a significant increase in TEWL from Day 0 to Days 3 and 7.
In a brief report titled, “An Analysis of Marketing Trends for the Approval of Cryolipolysis Devices by the United States Food and Drug Administration [FDA],” Wang et al reviewed records from a public FDA database for premarket approval of cryolipolysis devices approved between January 1, 2000, and July 15, 2018. The authors identified 11 devices that received 510(k) premarket approval, with an increasing number of devices available since 2012. In addition, expansion of product indications for use in patients with a body mass index (BMI) of up to 43kg/m2 was observed; however, the authors noted there is a lack of research for these indications, warning against potential marketing of these devices that distorts clinical expectations and misinforms consumers.
Finally, make sure to check out our online-only exclusive this month, where we feature original research by Davó et al titled, “Efficacy of an Antiaging Treatment Against Environmental Factors: Deschampsia antarctica Extract and High-tolerance Retinoids Combination.” Here, researchers evaluated the efficacy and tolerability of a topical antiaging regimen comprising high-concentration retinoids, Deschampsia antarctica extract, and niacinamide in 22 female volunteers living in a heavily polluted city. Assessments of facial aging, wrinkles, viscoelasticity, and firmness were completed at baseline, Day 30, and Day 90. At Day 90, a significant improvement in firmness (41.7%) and viscoelasticity (12.8%) were observed. Tolerance for treatment was rated as “good” or “very good” in 86.5 percent of the volunteers. Visit jcadonline.com/online-only-exclusives/ or jcad.mydigitalpublication.com/publication/?m=54680&l=1 to access this article, as well as our past online-only exclusives features.
We hope you enjoy this issue of JCAD. As always, we welcome your feedback and submissions.
James Q. Del Rosso, DO, FAOCD—Editor-in-Chief, Clinical Dermatology
Wm. Philip Werschler, MD, FAAD, FAACS—Editor-in-Chief, Aesthetic Dermatology
Seemal R. Desai, MD, FAAD— Associate Editor